drugset / Trial / NCT00550576

Antibodies to Digoxin for Bipolar Disorder

NCT00550576 ↗

Phase 2 Completed 18 enrolled Rambam Health Care Campus
NaSingle-groupSingle-blindTreatment

Summary

Subjects suffering from bipolar disorders treated with specific medications will give their informed concent and will receive intravenously only one dose of Digoxin antibodies (Fab). Their response to this therapy will be measured accordingly.Previous medications will be not changed A base line serum Endogenous Digitalis-like Compounds (DLC)levels will be measured using a specific laboratory technique and these compounds will be measured at 6 and 24 hours after Fab therapy. Patients also will be followed using clinical and psychological tests

Timeline

Start
2007-10
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Digibind Protein / enzyme biologic — Intravenous

Indications